ECE2008 Poster Presentations Obesity (94 abstracts)
1Institute of Endocrinology, Diabetes and Diseases of Metabolism, Belgrade, Serbia; 2Medical Faculty, Institute of Physiology, Belgrade, Serbia; 3Medical Faculty, Institute of Nutrition, Belgrade, Serbia; 4Medical Faculty, Institute of Microbiology and Immunology, Belgrade, Serbia.
Visfatin is a newly discovered adipokine found in abundance in visceral fat. Leptin is well known marker of fat mass in the body but also one aspect of leptin is its action as a proinflammatory cytokine. Recent studies, both in vitro and in vivo, indicated that visfatin is also one of the inflammatory cytokines, although the relationship between visfatin and insulin resistance remains still unclear. The aim of our study was to assess the association between visfatin and leptin levels in circulation and those of C-reactive protein (CRP), as marker of systemic inflammation, and also to investigate their relationship with insulin sensitivity index in obese women. In that order, thirty obese women (BMI=35.59±0.83 kg/m2, age=35.53±1.59 years) were included in the study. In each of the investigated subjects, following parameters were measured: Visfatin (EIA Phoenix, ng/ml), Leptin (Linco RIA, ng/ml), hs-CRP and M index (mg/kg per min) during euglycemic clamp studies as a marker of insulin sensitivity. Significant positive correlation was found between leptin levels and and CRP (r=0.435, P<0.05) while there were no correlation between leptin and M index (r=−0.128, P>0.05). There were no significant correlation between visfatin and CRP (r=−0.029, P>0.05), while visfatin significantly correlated with insulin sensitivity (M index) (r=0.309, P=0.055). There was significant negative correlation between CRP and M index (r=−0.439, P=0.001). In conclusion, according our results, visfatin levels are in significant positive correlation with insulin sensitivity index calculated during euglucaemic clamp, while there was no significant correlation between visfatin and CRP in obese women. Leptin seems to be a better marker of inflammatory state than visfatin in obese women.